These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37177895)

  • 21. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS; Silverberg JI; Cork MJ; Guttman-Yassky E; Lockshin B; Irvine AD; Kim MB; Kabashima K; Chen Z; Lu Y; Bansal A; Rossi AB; Shabbir A
    JAMA Dermatol; 2023 Mar; 159(3):255-266. PubMed ID: 36723913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience.
    Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr; 2024 Feb; 115(2):T150-T158. PubMed ID: 38048951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience.
    Martínez-Doménech A; Zaragoza-Ninet V; Esteve-Martínez A; García-Rabasco A; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr; 2024 Feb; 115(2):150-158. PubMed ID: 37858860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Sun X; Chen Z; Akinlade B; Boklage S; Guillemin I; Kosloski MP; Kamal MA; O'Malley JT; Patel N; Graham NMH; Bansal A
    Br J Dermatol; 2021 May; 184(5):857-870. PubMed ID: 32969489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis.
    Patruno C; Potestio L; Fabbrocini G; Napolitano M
    Dermatol Ther; 2022 Dec; 35(12):e15933. PubMed ID: 36227462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dupilumab in Elderly Patients With Severe Atopic Dermatitis.
    Russo F; Milanesi N; Cartocci A; Bruzziches F; Tronconi G; Lazzeri L; D'erme AM; Bagnoni G; Gola M; Cinotti E; Rubegni P; Flori ML
    Dermatitis; 2021 Oct; 32(1S):S24-S27. PubMed ID: 33332865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
    Kamphuis E; Boesjes CM; Loman L; Kamsteeg M; Haeck I; Van Lynden-van Nes AMT; Politiek K; Van der Gang LF; De Graaf M; De Bruin-Weller MS; Schuttelaar MLA
    Acta Derm Venereol; 2024 Feb; 104():adv19454. PubMed ID: 38323500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
    Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
    Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of dupilumab on sleep disturbances in adult patients with severe atopic dermatitis.
    Milanesi N; Gola M; Cartocci A; Tronconi G; Bruzziches F; Flori ML; Rubegni P; Russo F
    Ital J Dermatol Venerol; 2022 Apr; 157(2):142-145. PubMed ID: 34282867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
    Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
    J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
    Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
    Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study.
    Ureña-Paniego C; Montero-Vílchez T; Sanabria-de-la-Torre R; Soto-Moreno A; Molina-Leyva A; Arias-Santiago S
    Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
    Husein-ElAhmed H; Steinhoff M
    J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.